Yoshimatsu K, Nagasu T
Cancer & Infectious Disease Research Unit, Tsukuba Research Laboratories, Eisai Co., Ltd.
Gan To Kagaku Ryoho. 1997 Jan;24(2):145-55.
Posttranslational farnesylation by farnesyltransferase (FTase) is critical for the function of ras oncogene product and FTase has attracted attention as the new target of anticancer agents. B956 and B1352, obtained from the screening of CAAX analog inhibitors of FTase, induced flat reversion and inhibited the anchorage independent growth of ras transformant and ras mutated human tumor cell lines through the inhibition of posttranslational modification of ras p21. Inhibition of tumor growth in vivo was caused by inhibition of ras processing. Methyl ester prodrug of B956 and B1352 showed antitumor activity in ras mutated human tumor xenograft model. FTase inhibitor has the potential to be developed as therapy for ras mutated human tumors.
法尼基转移酶(FTase)介导的翻译后法尼基化对于Ras癌基因产物的功能至关重要,并且FTase作为抗癌药物的新靶点已引起关注。通过筛选FTase的CAAX类似物抑制剂获得的B956和B1352,可诱导扁平逆转,并通过抑制Ras p21的翻译后修饰,抑制Ras转化细胞和Ras突变的人肿瘤细胞系的锚定非依赖性生长。体内肿瘤生长的抑制是由Ras加工过程的抑制引起的。B956和B1352的甲酯前药在Ras突变的人肿瘤异种移植模型中显示出抗肿瘤活性。FTase抑制剂有潜力被开发为Ras突变的人类肿瘤的治疗药物。